Thyroid hormones and cardiovascular system

Czech version

Authors: Zdeňka Límanová; Jan Jiskra
Authors‘ workplace: III. interní klinika 1. LF UK a VFN v Praze
Published in: Vnitř Lék 2016; 62(Suppl 3): 92-98
Category: Reviews

Overview

Cardiovascular system is essentially affected by thyroid hormones by way of their genomic and non-genomic effects. Untreated overt thyroid dysfunction is associated with higher cardiovascular risk. Although it has been studied more than 3 decades, in subclinical thyroid dysfunction the negative effect on cardiovascular system is much more controversial. Large meta-analyses within last 10 years have shown that subclinical hyperthyroidism is associated with higher cardiovascular risk than subclinical hypothyroidism. Conversely, in patients of age > 85 years subclinical hypothyroidism was linked with lower mortality. Therefore, subclinical hyperthyroidism should be rather treated in the elderly while subclinical hypothyroidism in the younger patients and the older may be just followed. An important problem on the border of endocrinology and cardiology is amiodarone thyroid dysfunction. Effective and safe treatment is preconditioned by distinguishing of type 1 and type 2 amiodarone induced hyperthyroidism. The type 1 should be treated with methimazol, therapeutic response is prolonged, according to recent knowledge immediate discontinuation of amiodarone is not routinely recommended and patient should be usually prepared to total thyroidectomy, or rather rarely ¹³¹I radioiodine ablation may be used if there is appropriate accumulation. In the type 2 there is a promt therapeutic response on glucocorticoids (within 1–2 weeks) with permanent remission or development of hypothyroidism. If it is not used for life-threatening arrhytmias, amiodarone may be discontinuated earlier (after several weeks). Amiodarone induced hypothyroidism is treated with levothyroxine without amiodarone interruption.

Key words:
amiodarone induced thyroid dysfunction – atrial fibrillation – cardiovascular risk – heart failure – hyperthyroidism – hypothyroidism – thyroid stimulating hormone

Sources

1. Thomayer J. Pathologie a therapie nemocí vnitřních. 4. ed. Bursík J, Kohout F, Praha 1921: 487–507.

2. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation 2010; 122(4): 385–393. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA>.

3. Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence. Heart Fail Rev 2010; 15(2): 155–169. Dostupné z DOI: <http://dx.doi.org/.1007/s10741–008–9126–6>.

4. Biondi B. Heart failure and thyroid dysfunction. Eur J Endocrinol 2012; 167(5): 609–618. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0627>.

5. Friesema EC, Ganguly S, Abdalla A et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278(41): 40128–40135.

6. Flamant F, Baxter JD, Forrest D et al. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev 2006; 58(4): 705–711.

7. Kliewer SA, Umesono K, Mangelsdorf DJ et al. Evans RM . Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992; 355(6359): 446–449.

8. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 2016; 12(2): 111–121. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2015.205>.

9. Vassy R, Nicolas P, Yin YL et al. Nongenomic effect of triiodothyronine on cell surface beta-adrenoceptors in cultured embryonic cardiac myocytes. Proc Soc Exp Biol Med 1997; 214(4): 352–358.

10. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Endocrinol (Oxf) 2014; 81(5): 633–641. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12538>.

11. Vanden Berge G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid 2014; 24(10): 1456–1465. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2014.0201>.

12. Fraczek MM, Łacka K. Thyroid hormone and the cardiovascular system. Pol Merkur Lekarski 2014; 37(219): 170–174.

13. Límanová Z, Šimonová J. Změny tyreoidáních hormonů u čerstvého srdečního infarktu. Vnitř Lék 1984; 30(12): 1177–1185.

14. Mayer O Jr, Simon J, Filipovský J et al. Hypothyroidism in coronary heart disease and its relation to selected risk factors. Vasc Health Risk Manag 2006; 2(4): 499–506.

15. Lee JJ, Pedley A, Marqusee E et al. Thyroid Function and Cardiovascular Disease Risk Factors in Euthyroid Adults: A Cross-Sectional and Longitudinal Study. Clin Endocrinol (Oxf) 2016. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.13124>.

16. Levarsie G, Molinaro S, Landi P et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167(14): 1526–1532.

17. Singer RB. Mortality in a complete 4-year follow up of 85-year-old residents of Leiden, classified by serum level of thyrotropin and thyroxine. J Insur Med 2006; 38(1): 14–19.

18. Ochs N, Auer R, Bauer DC et al. Metaanalysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148(11): 832–845.

19. Mariotti S. Mild hypothyroidism and ischemic heart disease: Is age the answer? J Clin Endocrinol Metab 2008; 93(8): 2969–2971. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–1237>.

20. Hyland KA, Arnold AM, Lee JS et al. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 2013; 98(2): 533–540. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–2180>.

21. Selmer C, Olesen JB, Hansen ML et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99(7): 2372–2382. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–4184>.

22. Grossman A, Weiss A, Koren-Morag N et al. Subclinical thyroid disease and mortality in the elderly: a retrospective cohort study. Am J Med 2016; 129(4): 423–430. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2015.11.027>.

23. Olivieri O, Girelli D, Azzizi M et al. Low selenium status in elderly influences thyroid hormones. Clin-Sci 1995; 89(6): 637–642.

24. Markovič NS, Djurica S, Brajovič M et al. Dilated cardiomyopathy with autoimmune disease of thyroid gland. Srp Arth Celok Lek 2005; 133(Suppl 1): 46–51.

25. Sawin CT, Geller A, Wolf P et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrilation in older persons. N Engl J Med 1994; 331(19): 1249–1952.

26. Maity S, Kar D, De k et al. Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment end energy depletion. J Endocrinol 2013; 217(2):215–228. Dostupné z DOI: <http://dx.doi.org/10.1530/JOE-12–0304>.

27. Tamer I, Sargin M, Sargin H et al. The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 2005; 52(4): 421–425.

28. Rodondi N, Bauer DC, Cappola AR et al. Subclinical thyroid disease linked with modest risk of heart disease and mortality. J Am Coll Cardiol 2008; 52(14): 1152–1159. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.07.009>.

29. Cappola AR, Fried L, Arnold A et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295(9): 1033–1041.

30. Völzke H, Schwahn C, Wallaschofski H et al. Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab 2007; 92(7): 2421–2429.

31. Singh S, Duggal J, Molnar J et al. Impact of subclinical hyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008; 125(1): 41–48.

32. Collet TH, Gussekloo J, Bauer DC et al. Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10): 799–809. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2012.402>.

33. Haentjens P, Van Meerhaeghe A, Poppe K et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159(3): 329–341. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0110>.

34. Yang LB, Jiang DQ, Qi WB et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012; 167(1): 75–84. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0015>.

35. Sapp JL, Wells GA, Parkash R et al. Ventricular tachycardiac ablation versus escalation of antiarrhytmic drugs. New Engl J Med 2016; 375(2): 111–121. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1513614>.

36. Batcher EL, Tang XC, Singh BN et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med 2007; 120(10): 880.

37. van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3‘-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996; 137(7): 2807–2814.

38. Ross DS. Amiodarone and thyroid dysfunction. Up to Date. Section editor Cooper DS. Dostupné z WWW: http://www.uptodate.com/contents/amiodarone-and-thyroid-dysfunction.

39. Maqdasy S, Batisse-Lignier M, Auclair C et al. Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. Am J Cardiol 2016; 117(7): 1112–1116. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2016.01.003>.

40. Uzan L, Guignat L, Meune C et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 2006; 29(3): 231.

41. Eskes SA, Endert E, Fliers E et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab 2012; 97(2): 499–506. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–2390>.

42. Kurnik D, Loebstein R, Farfel Z et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83(2): 107.

43. Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs 2004; 13(4): 415–426.